Auto saved by Logseq

pages/STOP2030___STAB.md

@@ -24,4 +24,5 @@ alias:: STOP2030/Advisory Board
 		- We're establishing internal communication channels that keep all partners engaged with the project and updated.
 		- We're planning a media training course to be delivered to all partners
 		-
-	-
+	-
+-

pages/STOP2030___Web___Posts.md

@@ -1,6 +1,7 @@
 # [[WHO]] visit
 	-
 - # REALISE study registration
+  collapsed:: true
 	- ## The design of our REALISE study is now complete, and published
 	- #+BEGIN_VERSE
 	  At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). We are happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our largest clinical trial.
@@ -30,4 +31,6 @@
 	  The clinical trial will have two arms, randomized by school. One arm will receive a single dose of the fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and 14 years old; alb 400mg/ivm 18mg for those aged 15-17), while the other arm, serving as an active control group, will receive a single dose of albendazole 400mg, the current standard.
 	  
 	  If you want to review the full protocol, please visit the REALISE study's page on clinicaltrials.gov or PACTR (trial id: PACTR202402529220760).
-	  #+END_VERSE
+	  #+END_VERSE
+- # First STAB meeting
+	- ## Our project start